


ARCTIC AURORA BIOTECH SELECT

Healthy returns from transforming medicine


ARCTIC
ASSET MANAGEMENT

REASONS TO INVEST

-  **Pure biotech exposure**
-  **Investing in innovative companies**
-  **Long-term growth potential**



Top 5 positions



AUM	NOK 210m
Start date	09.06.2021
Reference index	NASDAQ Biotech
Fund type	Equity fund (UCITS)
SFDR	Article 8
PRIIP Risk class (1-7)	5
Management fee	1.25% p.a.
Performance fee	15% p.a.
Portfolio managers:	Ulrica Slåne Bjerke Torbjørn Bjerke Daniel Bolanowski
Analyst	Mark Fábíán

INVESTMENT APPROACH

The fund achieves excess returns from investing in the most innovative companies developing new treatments that significantly changes the life of patients to the benefit for society.


Investment positions in early-stage biotech are limited in size to control project specific risks.

A large and attractive universe enables investments in several companies.


Balanced mix of cash positive and non-cash positive companies.

The investment team has severe investment experience and thorough understanding of the biotech sector.

Increasing global life expectancy makes oncology a key investment field



An investment in AABS is a direct contributor to UN's SDG 3



This one pager has been produced by Arctic Asset Management and distributed for information only and should, under any circumstances, not be considered as an investment advice. Data included herein might be incorrect.

Historical returns and performance are no guarantee for future returns and performance.